Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 333


Effect of Hepatitis B virus on Steatosis in Hepatitis C virus co-infected subjects: a multi-center study and systematic review.

Goossens N, de Vito C, Mangia A, Clément S, Cenderello G, Barrera F, D'Ambrosio R, Coppola N, Zampino R, Stanzione M, Adinolfi LE, Wedemeyer H, Semmo N, Müllhaupt B, Semela D, Malinverni R, Moradpour D, Heim M, Trincucci G, Rubbia-Brandt L, Negro F; BOSTIC Study Group.

J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12891. [Epub ahead of print]


NHERF1 Between Promises and Hopes: Overview on Cancer and Prospective Openings.

Centonze M, Saponaro C, Mangia A.

Transl Oncol. 2018 Feb 15;11(2):374-390. doi: 10.1016/j.tranon.2018.01.006. [Epub ahead of print] Review.


What clinical, functional, and psychological factors before treatment are predictors of poor quality of life in cancer patients at the end of chemotherapy?

Mangia AS, Coqueiro NLO, Azevedo FC, Araujo HTDS, Amorim EO, Alves CNR, Camargo C, Fonseca AJD.

Rev Assoc Med Bras (1992). 2017 Nov;63(11):978-987. doi: 10.1590/1806-9282.63.11.978.


Frizzled-10 and cancer progression: Is it a new prognostic marker?

Scavo MP, Fucci L, Caldarola L, Mangia A, Azzariti A, Simone G, Gasparini G, Krol S.

Oncotarget. 2017 Dec 12;9(1):824-830. doi: 10.18632/oncotarget.23159. eCollection 2018 Jan 2.


TLR7 Agonist Increases Responses Of HBV-Specific T Cells And Natural Killer Cells In Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues.

Boni C, Vecchi A, Rossi M, Laccabue D, Giuberti T, Alfieri A, Lampertico P, Grossi G, Facchetti F, Brunetto MR, Coco B, Cavallone D, Mangia A, Santoro R, Piazzolla V, Lau A, Gaggar A, Subramanian GM, Ferrari C.

Gastroenterology. 2018 Jan 26. pii: S0016-5085(18)30072-6. doi: 10.1053/j.gastro.2018.01.030. [Epub ahead of print]


Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection.

Huang H, Duggal P, Thio CL, Latanich R, Goedert JJ, Mangia A, Cox AL, Kirk GD, Mehta S, Aneja J, Alric L, Donfield SM, Cramp ME, Khakoo SI, Tobler LH, Busch M, Alexander GJ, Rosen HR, Edlin BR, Segal FP, Lauer GM, Thomas DL, Daly MJ, Chung RT, Kim AY.

Sci Rep. 2017 Nov 20;7(1):15843. doi: 10.1038/s41598-017-16011-2.


Hierarchical clustering analysis identifies metastatic colorectal cancers patients with more aggressive phenotype.

Opinto G, Silvestris N, Centonze M, Graziano G, Pinto R, Fucci L, Simone G, Mangia A.

Oncotarget. 2017 Sep 23;8(50):87782-87794. doi: 10.18632/oncotarget.21213. eCollection 2017 Oct 20.


Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.

Bhardwaj N, Ragonnet-Cronin M, Murrell B, Chodavarapu K, Martin R, Chang S, Miller MD, Feld JJ, Sulkowski M, Mangia A, Wertheim JO, Osinusi A, McNally J, Brainard D, Mo H, Svarovskaia ES.

J Viral Hepat. 2017 Nov 7. doi: 10.1111/jvh.12825. [Epub ahead of print]


NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients.

Mangia A, Scarpi E, Partipilo G, Schirosi L, Opinto G, Giotta F, Simone G.

Oncotarget. 2017 Jul 22;8(39):65730-65742. doi: 10.18632/oncotarget.19444. eCollection 2017 Sep 12.


TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C.

John M, Metwally M, Mangia A, Romero-Gomez M, Berg T, Sheridan D, George J, Eslam M.

Gastroenterology. 2017 Nov;153(5):1448-1449. doi: 10.1053/j.gastro.2017.04.056. Epub 2017 Oct 6. No abstract available.


Next generation beta adrenoreceptor agonists for the treatment of asthma.

Crisafulli E, Frizzelli A, Fantin A, Manco A, Mangia A, Pisi G, Fainardi V, Alfieri V, Aiello M, Bertorelli G, Chetta A.

Expert Opin Pharmacother. 2017 Oct;18(14):1499-1505. doi: 10.1080/14656566.2017.1378348. Epub 2017 Sep 14. Review.


Grape seed extracts modify the outcome of oxaliplatin in colon cancer cells by interfering with cellular mechanisms of drug cytotoxicity.

Porcelli L, Iacobazzi RM, Quatrale AE, Bergamini C, Denora N, Crupi P, Antonacci D, Mangia A, Simone G, Silvestris N, Azzariti A.

Oncotarget. 2017 Feb 7;8(31):50845-50863. doi: 10.18632/oncotarget.15139. eCollection 2017 Aug 1.


Editorial: good news to patients with thalassaemia-HCV clearance made easy with direct acting antivirals. Authors' reply.

Mangia A, Piazzolla V, Santoro R.

Aliment Pharmacol Ther. 2017 Sep;46(6):629-630. doi: 10.1111/apt.14251. No abstract available.


Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis.

Asselah T, Bourgeois S, Pianko S, Zeuzem S, Sulkowski M, Foster GR, Han L, McNally J, Osinusi A, Brainard DM, Subramanian GM, Gane EJ, Feld JJ, Mangia A.

Liver Int. 2018 Mar;38(3):443-450. doi: 10.1111/liv.13534. Epub 2017 Oct 22.


Transcallosal Inhibition during Motor Imagery: Analysis of a Neural Mass Model.

Mangia AL, Ursino M, Lannocca M, Cappello A.

Front Comput Neurosci. 2017 Jun 30;11:57. doi: 10.3389/fncom.2017.00057. eCollection 2017.


VEGF and TWIST1 in a 16-biomarker immunoprofile useful for prognosis of breast cancer patients.

Schirosi L, De Summa S, Tommasi S, Paradiso A, Gasparini G, Popescu O, Simone G, Mangia A.

Int J Cancer. 2017 Nov 1;141(9):1901-1911. doi: 10.1002/ijc.30868. Epub 2017 Jul 20.


Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection.

Mangia A, Sarli R, Gamberini R, Piga A, Cenderello G, Piazzolla V, Santoro R, Caruso V, Quarta A, Ganga R, Copetti M, Forni G.

Aliment Pharmacol Ther. 2017 Aug;46(4):424-431. doi: 10.1111/apt.14197. Epub 2017 Jun 29.


Long-term persistence of HCV NS5A resistance associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir.

Wyles D, Mangia A, Cheng W, Shafran S, Schwabe C, Ouyang W, Hedskog C, McNally J, Brainard DM, Doehle BP, Svarovskaia E, Miller MD, Mo H, Dvory-Sobol H.

Antivir Ther. 2017 Jun 26. doi: 10.3851/IMP3181. [Epub ahead of print]


Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras.

Susser S, Dietz J, Schlevogt B, Zuckerman E, Barak M, Piazzolla V, Howe A, Hinrichsen H, Passmann S, Daniel R, Cornberg M, Mangia A, Zeuzem S, Sarrazin C.

J Hepatol. 2017 Oct;67(4):680-686. doi: 10.1016/j.jhep.2017.05.027. Epub 2017 Jun 13.


Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study.

Mangia A, Foster GR, Berg CP, Curescu M, Ledinghen V, Habersetzer F, Manolakopoulos S, Negri E, Papatheodoridis G, Ahlers S, Castillo M, Bakalos G, Mauss S; PegBase Group Investigators.

Ann Gastroenterol. 2017;30(3):327-343. doi: 10.20524/aog.2017.0136. Epub 2017 Mar 23.


The Use of IMMUs in a Water Environment: Instrument Validation and Application of 3D Multi-Body Kinematic Analysis in Medicine and Sport.

Mangia AL, Cortesi M, Fantozzi S, Giovanardi A, Borra D, Gatta G.

Sensors (Basel). 2017 Apr 22;17(4). pii: E927. doi: 10.3390/s17040927.


Comment on 'Renewed interest in the progesterone receptor in breast cancer'.

Simone G, Diotaiuti S, Digennaro M, Sambiasi D, De Summa S, Tommasi S, Altieri R, Mangia A, Dantona C, Paradiso A.

Br J Cancer. 2017 Jul 11;117(2):e1. doi: 10.1038/bjc.2017.90. Epub 2017 Apr 11. No abstract available.


IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis.

Eslam M, McLeod D, Kelaeng KS, Mangia A, Berg T, Thabet K, Irving WL, Dore GJ, Sheridan D, Grønbæk H, Abate ML, Hartmann R, Bugianesi E, Spengler U, Rojas A, Booth DR, Weltman M, Mollison L, Cheng W, Riordan S, Mahajan H, Fischer J, Nattermann J, Douglas MW, Liddle C, Powell E, Romero-Gomez M, George J; International Liver Disease Genetics Consortium (ILDGC).

Nat Genet. 2017 May;49(5):795-800. doi: 10.1038/ng.3836. Epub 2017 Apr 10.


International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement.

Zignego AL, Ramos-Casals M, Ferri C, Saadoun D, Arcaini L, Roccatello D, Antonelli A, Desbois AC, Comarmond C, Gragnani L, Casato M, Lamprecht P, Mangia A, Tzioufas AG, Younossi ZM, Cacoub P; ISG-EHCV.

Autoimmun Rev. 2017 May;16(5):523-541. doi: 10.1016/j.autrev.2017.03.004. Epub 2017 Mar 7. Review.


Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection.

Ramos-Casals M, Zignego AL, Ferri C, Brito-Zerón P, Retamozo S, Casato M, Lamprecht P, Mangia A, Saadoun D, Tzioufas AG, Younossi ZM, Cacoub P; International Study Group of Extrahepatic Manifestations related to HCV (ISG-EHCV).

J Hepatol. 2017 Jun;66(6):1282-1299. doi: 10.1016/j.jhep.2017.02.010. Epub 2017 Feb 20. Review. No abstract available.


The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B.

Thabet K, Chan HLY, Petta S, Mangia A, Berg T, Boonstra A, Brouwer WP, Abate ML, Wong VW, Nazmy M, Fischer J, Liddle C, George J, Eslam M.

Hepatology. 2017 Jun;65(6):1840-1850. doi: 10.1002/hep.29064. Epub 2017 Apr 28.


NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome.

Zeuzem S, Mizokami M, Pianko S, Mangia A, Han KH, Martin R, Svarovskaia E, Dvory-Sobol H, Doehle B, Hedskog C, Yun C, Brainard DM, Knox S, McHutchison JG, Miller MD, Mo H, Chuang WL, Jacobson I, Dore GJ, Sulkowski M.

J Hepatol. 2017 May;66(5):910-918. doi: 10.1016/j.jhep.2017.01.007. Epub 2017 Jan 18.


Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience.

Mangia A, Susser S, Piazzolla V, Agostinacchio E, De Stefano G, Palmieri V, Spinzi G, Carraturo I, Potenza D, Losappio R, Arleo A, Miscio M, Santoro R, Sarrazin C, Copetti M.

J Hepatol. 2017 Apr;66(4):711-717. doi: 10.1016/j.jhep.2016.12.002. Epub 2016 Dec 10.


IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study.

Mangia A, De Ledinghen V, Bailly F, Brahm J, Keiss J, Valantinas J, Rasmann N, Messinger D, Tatsch F, Bakalos G, Foster GR; Gen-C study group.

Springerplus. 2016 Nov 18;5(1):1990. eCollection 2016.


FISH testing of HER2 immunohistochemistry 1+ invasive breast cancer with unfavorable characteristics.

Petroni S, Caldarola L, Scamarcio R, Giotta F, Latorre A, Mangia A, Simone G.

Oncol Lett. 2016 Nov;12(5):3115-3122. Epub 2016 Sep 13.


Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?

Schirosi L, Strippoli S, Gaudio F, Graziano G, Popescu O, Guida M, Simone G, Mangia A.

BMC Cancer. 2016 Nov 18;16(1):905.


Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis.

Younossi ZM, Stepanova M, Feld J, Zeuzem S, Sulkowski M, Foster GR, Mangia A, Charlton M, O'Leary JG, Curry MP, Nader F, Henry L, Hunt S.

Clin Gastroenterol Hepatol. 2017 Mar;15(3):421-430.e6. doi: 10.1016/j.cgh.2016.10.037. Epub 2016 Nov 12.


β-catenin interaction with NHERF1 and RASSF1A methylation in metastatic colorectal cancer patients.

Schirosi L, Mazzotta A, Opinto G, Pinto R, Graziano G, Tommasi S, Fucci L, Simone G, Mangia A.

Oncotarget. 2016 Oct 18;7(42):67841-67850. doi: 10.18632/oncotarget.12280.


Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer.

Ribatti D, Nico B, Ruggieri S, Tamma R, Simone G, Mangia A.

Transl Oncol. 2016 Oct;9(5):453-457. doi: 10.1016/j.tranon.2016.07.002. Review.


International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement.

Ferri C, Ramos-Casals M, Zignego AL, Arcaini L, Roccatello D, Antonelli A, Saadoun D, Desbois AC, Sebastiani M, Casato M, Lamprecht P, Mangia A, Tzioufas AG, Younossi ZM, Cacoub P; ISG-EHCV coauthors.

Autoimmun Rev. 2016 Dec;15(12):1145-1160. doi: 10.1016/j.autrev.2016.09.006. Epub 2016 Sep 16. Review.


EEG-Based BCI System Using Adaptive Features Extraction and Classification Procedures.

Mondini V, Mangia AL, Cappello A.

Comput Intell Neurosci. 2016;2016:4562601. doi: 10.1155/2016/4562601. Epub 2016 Aug 17.


MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C.

Thabet K, Asimakopoulos A, Shojaei M, Romero-Gomez M, Mangia A, Irving WL, Berg T, Dore GJ, Grønbæk H, Sheridan D, Abate ML, Bugianesi E, Weltman M, Mollison L, Cheng W, Riordan S, Fischer J, Spengler U, Nattermann J, Wahid A, Rojas A, White R, Douglas MW, McLeod D, Powell E, Liddle C, van der Poorten D, George J, Eslam M; International Liver Disease Genetics Consortium.

Nat Commun. 2016 Sep 15;7:12757. doi: 10.1038/ncomms12757.


Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.

Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, Han L, McNally J, Osinusi A, Brainard DM, Subramanian GM, Natha M, Foster GR, Mangia A, Sulkowski M, Feld JJ.

Clin Infect Dis. 2016 Dec 1;63(11):1479-1481. Epub 2016 Aug 23.


Impact of body mass index (BMI) on the prognosis of high-risk early breast cancer (EBC) patients treated with adjuvant chemotherapy.

Gennari A, Amadori D, Scarpi E, Farolfi A, Paradiso A, Mangia A, Biglia N, Gianni L, Tienghi A, Rocca A, Maltoni R, Antonucci G, Bruzzi P, Nanni O.

Breast Cancer Res Treat. 2016 Aug;159(1):79-86. doi: 10.1007/s10549-016-3923-8. Epub 2016 Jul 26.


Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.

Younossi ZM, Stepanova M, Sulkowski M, Foster GR, Reau N, Mangia A, Patel K, Bräu N, Roberts SK, Afdhal N, Nader F, Henry L, Hunt S.

Clin Infect Dis. 2016 Oct 15;63(8):1042-1048. doi: 10.1093/cid/ciw496. Epub 2016 Jul 20.


Phytoliposome-Based Silibinin Delivery System as a Promising Strategy to Prevent Hepatitis C Virus Infection.

Ripoli M, Angelico R, Sacco P, Ceglie A, Mangia A.

J Biomed Nanotechnol. 2016 Apr;12(4):770-80.


Polymorphisms in STAT4 are not associated with treatment response and spontaneous clearance of hepatitis C virus in europeans.

Asimakopoulos A, Mangia A, Dore GJ, Lloyd AR, George J, Eslam M.

Hepatology. 2016 Dec;64(6):2264-2265. doi: 10.1002/hep.28626. Epub 2016 Jun 27. No abstract available.


Sofosbuvir and Velpatasvir for Patients with HCV Infection.

Foster GR, Mangia A, Sulkowski M.

N Engl J Med. 2016 Apr 28;374(17):1687-8. doi: 10.1056/NEJMc1601160. No abstract available.


Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes.

Eslam M, Mangia A, Berg T, Chan HL, Irving WL, Dore GJ, Abate ML, Bugianesi E, Adams LA, Najim MA, Miele L, Weltman M, Mollison L, Cheng W, Riordan S, Fischer J, Romero-Gomez M, Spengler U, Nattermann J, Rahme A, Sheridan D, Booth DR, McLeod D, Powell E, Liddle C, Douglas MW, van der Poorten D, George J; International Liver Disease Genetics Consortium.

Hepatology. 2016 Jul;64(1):34-46. doi: 10.1002/hep.28475. Epub 2016 Mar 30.


The current treatment of Hepatitis C.

Arleo A, Mangia A.

Minerva Gastroenterol Dietol. 2016 Jun;62(2):167-82. Epub 2016 Jan 22. Review.


Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance.

Danza K, Silvestris N, Simone G, Signorile M, Saragoni L, Brunetti O, Monti M, Mazzotta A, De Summa S, Mangia A, Tommasi S.

Cancer Biol Ther. 2016 Apr 2;17(4):400-6. doi: 10.1080/15384047.2016.1139244.


The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin.

Mangia A, Arleo A, Copetti M, Miscio M, Piazzolla V, Santoro R, Squillante MM.

Liver Int. 2016 Jul;36(7):971-6. doi: 10.1111/liv.13069. Epub 2016 Feb 7.


Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older.

Saab S, Park SH, Mizokami M, Omata M, Mangia A, Eggleton E, Zhu Y, Knox SJ, Pang P, Subramanian M, Kowdley K, Afdhal NH.

Hepatology. 2016 Apr;63(4):1112-9. doi: 10.1002/hep.28425. Epub 2016 Feb 22.


Nuclear PARP1 expression and its prognostic significance in breast cancer patients.

Mazzotta A, Partipilo G, De Summa S, Giotta F, Simone G, Mangia A.

Tumour Biol. 2016 May;37(5):6143-53. doi: 10.1007/s13277-015-4465-0. Epub 2015 Nov 27.


Supplemental Content

Loading ...
Support Center